Botulinum toxin type B for treatment of spasmodic dysphonia: a case report.

Abstract

Although treatment with botulinum toxin type A (BTXA) has become the standard of care for most patients with laryngeal dystonia, its use is limited by the development of resistance to the toxin in some patients. Botulinum toxin type B (BTXB) has been found to be safe and effective in the treatment of cervical dystonia, but it has not been used previously to treat spasmodic dysphonia. Our experience with BTXB in a patient who developed resistance to BTXA suggests that BTXB may be safe and effective for the treatment of laryngeal dystonia, as well.

• Authors: Robert Thayer Sataloff, Yolanda D Heman-Ackah, Lance L Simpson, Jong-Beak Park, Amy Zwislewski, Caren Sokolow, Steven Mandel
• Journal: Journal of voice : official journal of the Voice Foundation (J Voice) Vol. 16 Issue 3 Pg. 422-4 (Sep 2002) ISSN: 0892-1997 [Print] United States
• PMID: 12395995 (Publication Type: Case Reports, Journal Article)

Chemical References

• rimabotulinumtoxinB
• Botulinum Toxins
• Botulinum Toxins, Type A

Topics

• Botulinum Toxins (administration & dosage, therapeutic use)
• Botulinum Toxins, Type A
• Dose-Response Relationship, Drug
• Drug Administration Schedule
• Humans
• Male
• Middle Aged
• Pharyngeal Diseases (drug therapy, physiopathology)
• Voice Disorders (drug therapy)